Correlation of Tumour Subtype with Long-term Outcome in Small Breast Carcinomas: a Swedish Population-based Retrospective Cohort Study

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2022 Aug 6

PMID 35933487

Authors

Gunilla Rask

Anoosheh Nazemroaya

Malin Jansson

Charlotta Wadsten

Greger Nilsson

Carl Blomqvist

Lars Holmberg

Fredrik Warnberg

Malin Sund

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate if molecular subtype is associated with outcome in stage 1 breast cancer (BC).

Methods: Tissue samples from 445 women with node-negative BC ≤ 15 mm, treated in 1986-2004, were classified into surrogate molecular subtypes [Luminal A-like, Luminal B-like (HER2-), HER2-positive, and triple negative breast cancer (TNBC)]. Information on treatment, recurrences, and survival were gathered from medical records.

Results: Tumour subtype was not associated with overall survival (OS). Luminal B-like (HER2-) and TNBC were associated with higher incidence of distant metastasis at 20 years (Hazard ratio (HR) 2.26; 95% CI 1.08-4.75 and HR 3.24; 95% CI 1.17-9.00, respectively). Luminal B-like (HER2-) and TNBC patients also had worse breast cancer-specific survival (BCSS), although not statistically significant (HR 1.53; 95% CI 0.70-3.33 and HR 1.89; 95% CI 0.60-5.93, respectively). HER2-positive BC was not associated with poor outcome despite no patient receiving HER2-targeted therapy, with most of these tumours being ER+.

Conclusions: Stage 1 TNBC or Luminal B-like (HER2-) tumours behave more aggressively. Women with HER2+/ER+ tumours do not have an increased risk of distant metastasis or death, absent targeted treatment.

Citing Articles

A Novel Compound from the Phenylsulfonylpiperazine Class: Evaluation of In Vitro Activity on Luminal Breast Cancer Cells.

da Silva F, Cassiano Martinho A, Ferreira H, Siqueira R, Arruda V, Guerra J Molecules. 2024; 29(18).

PMID: 39339466 PMC: 11433764. DOI: 10.3390/molecules29184471.

Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.

Devarajan R, Izzi V, Peltoketo H, Rask G, Kauppila S, Vaisanen M J Clin Invest. 2023; 133(18).

PMID: 37498672 PMC: 10702473. DOI: 10.1172/JCI159181.

Recent Advances in Optimizing Radiation Therapy Decisions in Early Invasive Breast Cancer.

Riaz N, Jeen T, Whelan T, Nielsen T Cancers (Basel). 2023; 15(4).

PMID: 36831598 PMC: 9954587. DOI: 10.3390/cancers15041260.

Strict definition of a small tumor in breast cancer should be revisited.

Sanli A, Altundag K Breast Cancer Res Treat. 2022; 196(1):241.

PMID: 36056296 DOI: 10.1007/s10549-022-06734-w.

References

Fergenbaum J, Garcia-Closas M, Hewitt S, Lissowska J, Sakoda L, Sherman M . Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2004; 13(4):667-72. View

Kolben T, Harbeck N, Wuerstlein R, Schubert-Fritschle G, Bauerfeind I, Schrodi S . Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry. Breast. 2014; 24(1):24-31. DOI: 10.1016/j.breast.2014.10.007. View

Tryfonidis K, Zardavas D, Cardoso F . Small breast cancers: when and how to treat. Cancer Treat Rev. 2014; 40(10):1129-36. DOI: 10.1016/j.ctrv.2014.09.004. View

Prat A, Chon U Cheang M, Martin M, Parker J, Carrasco E, Caballero R . Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2012; 31(2):203-9. PMC: 3532392. DOI: 10.1200/JCO.2012.43.4134. View

Park Y, Kim S, Cho E, La Choi Y, Ok O, Baek H . A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?. Breast Cancer Res Treat. 2009; 119(3):653-61. DOI: 10.1007/s10549-009-0665-x. View

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

Livi L, Meattini I, Saieva C, Franzese C, Di Cataldo V, Greto D . Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer. 2011; 118(13):3236-43. DOI: 10.1002/cncr.26647. View

Collins L, Botero M, Schnitt S . Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005; 123(1):16-20. DOI: 10.1309/hcf035n9wk40etj0. View

Combs S, Han G, Mani N, Beruti S, Nerenberg M, Rimm D . Loss of antigenicity with tissue age in breast cancer. Lab Invest. 2015; 96(3):264-9. DOI: 10.1038/labinvest.2015.138. View

10.

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793):771-84. PMC: 3163848. DOI: 10.1016/S0140-6736(11)60993-8. View

11.

Lundgren C, Bendahl P, Borg A, Ehinger A, Hegardt C, Larsson C . Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Res Treat. 2019; 178(2):459-467. PMC: 6797629. DOI: 10.1007/s10549-019-05378-7. View

12.

Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales A . Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005; 123(1):21-7. DOI: 10.1309/4wv79n2ghj3x1841. View

13.

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403-410. Histopathology. 2002; 41(3A):151-2, discussion 152-3. View

14.

Chia S, Speers C, Bryce C, Hayes M, Olivotto I . Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol. 2004; 22(9):1630-7. DOI: 10.1200/JCO.2004.09.070. View

15.

Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S . Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res. 2014; 16(3):R65. PMC: 4095689. DOI: 10.1186/bcr3679. View

16.

Olszewski A, Migdady Y, Boolbol S, Klein P, Boachie-Adjei K, Sakr B . Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. Breast Cancer Res Treat. 2013; 138(1):215-23. DOI: 10.1007/s10549-013-2423-3. View

17.

Grillo F, Bruzzone M, Pigozzi S, Prosapio S, Migliora P, Fiocca R . Immunohistochemistry on old archival paraffin blocks: is there an expiry date?. J Clin Pathol. 2017; 70(11):988-993. DOI: 10.1136/jclinpath-2017-204387. View

18.

Hugh J, Hanson J, Chon U Cheang M, Nielsen T, Perou C, Dumontet C . Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009; 27(8):1168-76. PMC: 2667821. DOI: 10.1200/JCO.2008.18.1024. View

19.

Allott E, Geradts J, Sun X, Cohen S, Zirpoli G, Khoury T . Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. Breast Cancer Res. 2016; 18(1):68. PMC: 4924300. DOI: 10.1186/s13058-016-0725-1. View

20.

Blows F, Driver K, Schmidt M, Broeks A, van Leeuwen F, Wesseling J . Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010; 7(5):e1000279. PMC: 2876119. DOI: 10.1371/journal.pmed.1000279. View